
Dr. Miron on first-line treatment selection in bladder cancer
Miron presented a study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on survival outcomes in patients who received immunotherapy in the second-line setting.
Benjamin Miron, MD, shares his expertise on treatment selection in the first-line setting for patients with urothelial carcinoma.
Miron, a second-year hematology/oncology fellow at Fox Chase Cancer Center, presented a
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


















